SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001328143-21-000072
Filing Date
2021-08-09
Accepted
2021-08-09 16:04:13
Documents
13
Period of Report
2021-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adms-20210809.htm   iXBRL 8-K 36167
2 EX-99.1 adms991q22021earningsrelea.htm EX-99.1 75568
  Complete submission text file 0001328143-21-000072.txt   260676

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adms-20210809.xsd EX-101.SCH 1902
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adms-20210809_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adms-20210809_pre.xml EX-101.PRE 13046
6 EXTRACTED XBRL INSTANCE DOCUMENT adms-20210809_htm.xml XML 10972
Mailing Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608
Business Address 1900 POWELL ST., SUITE 1000 EMERYVILLE CA 94608 510-450-3554
Adamas Pharmaceuticals Inc (Filer) CIK: 0001328143 (see all company filings)

IRS No.: 421560076 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36399 | Film No.: 211156405
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences